NASDAQ:GRCL

Gracell Biotechnologies Earning Date

USA |NASDAQ |USD

GRCL Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
- Sep 30, 2021 - $-0.04 -
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
- Sep 30, 2021 - $0.00 $0.00

GRCL Earnings Date & History Chart

GRCL Earnings & Revenue Forecast

GRCL Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 3 $-0.15 $-0.30 $-0.07
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 2 $-0.61 $-0.99 $-0.23
Dec 2022 3 $-0.75 $-1.53 $-0.36

GRCL Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.15 $-0.17 $-0.17
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 0 / 0 $-0.61 $-1.10 $-1.10
Dec 2022 0 / 0 $-0.75 $-0.83 $-0.83

GRCL Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 3 $0.00 $0.00 $0.00
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 3 $0.00 $0.00 $0.00
Dec 2022 3 $0.00 $0.00 $0.00

GRCL Earnings Date & Revenue History

GRCL Earnings History

|
Show More
Show More

GRCL Revenue History

|
Show More
Show More

Gracell Biotechnologies Next Earnings Date & Report

GRCL Aug 2021 (FQ) Earnings Date & Report Preview

Gracell Biotechnologies Previous Earnings Dates & Reports

GRCL Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Gracell Biotechnologies's previous earnings date was Aug 17, 2021 for its fiscal quarter ended Jun 30, 2021.

GRCL's earnings per share (EPS) was $-0.04, beating the consensus analysts forecast of $-0.15 by 73.33%.

The EPS was higher than the previous fiscal quarter (Mar 2021) by -20.00%.

Revenues were $0.00.

The company reported a net income of $-96.22M.

GRCL ended the quarter with $153.19M in total debt, an increase of 10.50% compared to the previous quarter.

GRCL Previous Earnings Date & Report Recap: Dec 2020 (FY)

Gracell Biotechnologies's previous annual earnings date was Mar 9, 2021 for its fiscal year ended Dec 31, 2020.

GRCL's earnings per share (EPS) was $-0.16.

Revenues were $0.00.

The company reported a net income of $-211.90M.

Gracell Biotechnologies reported a free cash flow of $-277.55M for its fiscal year, compared to $-191.82M a year ago.

The company ended the fiscal year with $102.89M in total debt, a decrease of -25.82% compared to the previous year.